Anticancer drug R&D landscape in China.

In terms of treatment strategies, IO therapy has surpassed targeted therapy as the most popular strategy in anticancer drug R&D [[1]]. Types of cell therapy expanded from one single class (CAR-T) to six classes including CAR-T, autologous circulating T cells, NK cell-derived therapies, TCR-T, engineered T cells, and tumor-infiltrating T cells (Fig. More diverse cancer types studied in phase 1 trials 67.9% (247 trials) of phase 1 oncology trials enrolled patients with specific types of cancer. [Extracted from the article]